@article{1f6f83b9de254a40adb7e52ea63431a6,
title = "Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report",
abstract = "This consensus document provides an update for pathologists and clinicians about the interpretation of biopsy results and use of this information in the management of hematopoietic cell transplantation patients. Optimal sampling and tissue preparation are discussed. Minimal criteria for the diagnosis of graft-versus-host disease (GVHD) are proposed, together with specific requirements for the diagnosis of chronic GVHD. Four final diagnostic categories (no GVHD, possible GVHD, consistent with GVHD, and definite GVHD) reflect the integration of histopathology with clinical, laboratory, and radiographic information. Finally, the Working Group developed a set of worksheets to facilitate communication of clinical information to the interpreting pathologist and to aid in clinicopathologic correlation studies. Form are available http://www.aaasbmt.org/cGvHD_Guidelines. The recommendations of the Working Group represent a consensus opinion supplemented by evaluation of available peer-reviewed literature. Consensus recommendations and suggested data-capture forms should be validated in prospective clinicopathologic studies.",
keywords = "Allogeneic hematopoietic cell transplantation, Chronic graft-versus-host disease, Consensus diagnosis, Pathology",
author = "Shulman, {Howard M.} and David Kleiner and Lee, {Stephanie J.} and Thomas Morton and Pavletic, {Steven Z.} and Evan Farmer and Moresi, {J. Margaret} and Joel Greenson and Anne Janin and Martin, {Paul J.} and George McDonald and Flowers, {Mary E.D.} and Maria Turner and Jane Atkinson and Jay Lefkowitch and Washington, {M. Kay} and Prieto, {Victor G.} and Kim, {Stella K.} and Zsolt Argenyi and Diwan, {A. Hafeez} and Asif Rashid and Kim Hiatt and Dan Couriel and Kirk Schultz and Sharon Hymes and Vogelsang, {Georgia B.}",
note = "Funding Information: This project was supported by the National Institutes of Health{\textquoteright}s National Cancer Institute, Office of the Director, Cancer Therapy Evaluation Program, Intramural Research Program, and Center for Cancer Research; the National Heart Lung and Blood Institute, Division of Blood Diseases and Resources; Office of Rare Diseases, National Institutes of Health, Office of the Director; National Institute of Allergy and Infectious Disease, Transplantation Immunology Branch; the Health Resources and Services Administration, Division of Transplantation; and the Naval Medical Research Center, C.W. Bill Young/Department of Defense Marrow Donor Recruitment and Research Program. The authors would also like to acknowledge the following individuals and organizations that, by their participation, made this project possible: the American Society for Blood and Marrow Transplantation, the Center for International Bone and Marrow Transplant Research, the Blood and Marrow Transplant Clinical Trials Network, the Canadian Blood and Marrow Transplant Group, the European Group for Blood and Marrow Transplantation, the Pediatric Blood and Marrow Transplant Consortium, and the representatives of the South American transplant centers (Drs. Luis F. Bouzas and Vaneuza Funke). This project was conducted in coordination with the American Society for Clinical Oncology and the American Society of Hematology (liaisons, Dr. Michael Bishop and Jeff Coughlin). The organizers are also in debt to the patients and patient and research advocacy groups who made this process much more meaningful by their engagement; special thanks also to Paula Kim, who coordinated these efforts. The National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD Steering Committee included the following: Steven Pavletic and Georgia Vogelsang (project chairs), LeeAnn Jensen (planning committee chair), Lisa Filipovich (Diagnosis and Staging), Howard Shulman (Histopathology), Kirk Schultz (Biomarkers), Dan Couriel (Ancillary and Supportive Care), Stephanie Lee (Design of Clinical Trials), James Ferrara, Mary Flowers, Jean Henslee-Downey, Paul Martin, Barbara Mittleman, Shiv Prasad, Donna Przepiorka, Douglas Rizzo, Daniel Weisdorf, and Roy Wu (members). The project group also recognizes the contributions of numerous colleagues in the field of blood and marrow transplantation, medical specialists and consultants, the pharmaceutical industry, and the National Institutes of Health and US Food and Drug Administration professional staff for their intellectual input, dedication, and enthusiasm on the road to completion of these documents. ",
year = "2006",
month = jan,
doi = "10.1016/j.bbmt.2005.10.023",
language = "English (US)",
volume = "12",
pages = "31--47",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",
}